Media Coverage

Evolving Bioassay Strategies for Therapeutic Antibodies: Essential Information for Proving Biosimilarity

Bioprocess International

Biosimilars are poised to have an even bigger impact on both European and US markets, with mAbs representing the most attractive targets for developers of these follow-on products. Ulrike Herbrand of Charles River discusses in Bioprocess International.

Read the full article